









Markets
/
Stocks
/
nasdaq-cvm
/

CEL-SCI Corp

CVM

5.000USD

+0.100+2.04%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

40.08MMarket Cap

LossP/E TTM



CEL-SCI Corp

5.000

+0.100+2.04%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CEL-SCI Corp

Currency: USD Updated: 2026-02-06

Key Insights

CEL-SCI Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 141 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CEL-SCI Corp's Score

Industry at a Glance

Industry Ranking

141 / 392

Overall Ranking

286 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

CEL-SCI Corp Highlights

StrengthsRisks

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

Overvalued

The company’s latest PE is -0.80, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 285.12K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

25.000

Target Price

+410.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of CEL-SCI Corp is 5.93, ranking 311 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.93

Change



Financials

6.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CEL-SCI Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of CEL-SCI Corp is 7.16, ranking 160 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.80, which is -95.80% below the recent high of -0.03 and -466.49% above the recent low of -4.52.

Score

Industry at a Glance

Previous score

7.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of CEL-SCI Corp is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 300.00, with a high of 300.00 and a low of 300.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

25.000

Target Price

+410.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

CEL-SCI Corp

CVM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of CEL-SCI Corp is 6.95, ranking 134 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.28 and the support level at 4.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.88

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.165

Sell

RSI(14)

41.992

Neutral

STOCH(KDJ)(9,3,3)

14.738

Oversold

ATR(14)

0.635

Low Volatility

CCI(14)

-92.066

Neutral

Williams %R

83.732

Oversold

TRIX(12,20)

-0.025

Sell

StochRSI(14)

29.600

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

5.110

Sell

MA10

5.621

Sell

MA20

5.503

Sell

MA50

5.756

Sell

MA100

7.071

Sell

MA200

6.652

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of CEL-SCI Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 8.30%, representing a quarter-over-quarter decrease of 0.52%. The largest institutional shareholder is The Vanguard, holding a total of 285.12K shares, representing 3.39% of shares outstanding, with 21.22% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lincoln Alternative Strategies LLC

555.00K

The Vanguard Group, Inc.

Star Investors

292.56K

+59.69%

Commonwealth Financial Network

175.21K

BlackRock Institutional Trust Company, N.A.

136.09K

+19.12%

Kersten (Geert R)

69.76K

-4.97%

MAI Capital Management, LLC

76.86K

+18.37%

Geode Capital Management, L.L.C.

60.75K

+134.40%

BofA Global Research (US)

40.98K

-0.01%

State Street Investment Management (US)

23.27K

U.S. Bancorp Asset Management, Inc.

8.70K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CEL-SCI Corp is 2.09, ranking 254 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.